Suppr超能文献

在 HSPCs 中同时进行敲除敲入基因组编辑策略,可有效抑制 CCR5-和 CXCR4 嗜性 HIV-1 感染。

A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.

机构信息

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Institute for Stem Cell Biology & Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark; Aarhus Institute of Advanced Studies (AIAS), Aarhus University, 8000 Aarhus, Denmark.

出版信息

Cell Stem Cell. 2024 Apr 4;31(4):499-518.e6. doi: 10.1016/j.stem.2024.03.002.

Abstract

Allogeneic hematopoietic stem and progenitor cell transplant (HSCT) of CCR5 null (CCR5Δ32) cells can be curative for HIV-1-infected patients. However, because allogeneic HSCT poses significant risk, CCR5Δ32 matched bone marrow donors are rare, and CCR5Δ32 transplant does not confer resistance to the CXCR4-tropic virus, it is not a viable option for most patients. We describe a targeted Cas9/AAV6-based genome editing strategy for autologous HSCT resulting in both CCR5- and CXCR4-tropic HIV-1 resistance. Edited human hematopoietic stem and progenitor cells (HSPCs) maintain multi-lineage repopulation capacity in vivo, and edited primary human T cells potently inhibit infection by both CCR5-tropic and CXCR4-tropic HIV-1. Modification rates facilitated complete loss of CCR5-tropic replication and up to a 2,000-fold decrease in CXCR4-tropic replication without CXCR4 locus disruption. This multi-factor editing strategy in HSPCs could provide a broad approach for autologous HSCT as a functional cure for both CCR5-tropic and CXCR4-tropic HIV-1 infections.

摘要

异体造血干细胞和祖细胞移植(HSCT)的 CCR5 缺失(CCR5Δ32)细胞可以治愈 HIV-1 感染患者。然而,由于异体 HSCT 存在重大风险,CCR5Δ32 匹配的骨髓供体很少,并且 CCR5Δ32 移植不能抵抗 CXCR4 嗜性病毒,因此它不是大多数患者的可行选择。我们描述了一种针对自体 HSCT 的靶向 Cas9/AAV6 基因组编辑策略,可导致 CCR5 和 CXCR4 嗜性 HIV-1 耐药。编辑的人造血干细胞和祖细胞(HSPCs)在体内保持多谱系重​​殖能力,编辑的原代人 T 细胞强烈抑制 CCR5 嗜性和 CXCR4 嗜性 HIV-1 的感染。修饰率可促进 CCR5 嗜性复制完全丧失,并将 CXCR4 嗜性复制降低多达 2000 倍,而不会破坏 CXCR4 基因座。这种在 HSPCs 中的多因素编辑策略可以为自体 HSCT 提供广泛的方法,作为 CCR5 嗜性和 CXCR4 嗜性 HIV-1 感染的功能性治愈。

相似文献

9
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.
PLoS Pathog. 2011 Apr;7(4):e1002020. doi: 10.1371/journal.ppat.1002020. Epub 2011 Apr 14.
10
CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
Mol Ther. 2017 Aug 2;25(8):1782-1789. doi: 10.1016/j.ymthe.2017.04.027. Epub 2017 May 17.

引用本文的文献

1
CRISPR/Cas9 for achieving postintervention HIV control.
Curr Opin HIV AIDS. 2025 Sep 1;20(5):432-440. doi: 10.1097/COH.0000000000000963. Epub 2025 Jul 18.
3
Deep Thought on the HIV Cured Cases: Where Have We Been and What Lies Ahead?
Biomolecules. 2025 Mar 5;15(3):378. doi: 10.3390/biom15030378.
5
High-resolution Inference of Multiplexed Anti-HIV Gene Editing using Single-Cell Targeted DNA Sequencing.
bioRxiv. 2024 Aug 22:2024.01.24.576921. doi: 10.1101/2024.01.24.576921.

本文引用的文献

1
HIV-1 Infection of Long-Lived Hematopoietic Precursors In Vitro and In Vivo.
Cells. 2022 Sep 23;11(19):2968. doi: 10.3390/cells11192968.
4
Highlights of virtual CROI 2022.
Lancet HIV. 2022 Apr;9(4):e231. doi: 10.1016/S2352-3018(22)00075-3.
7
Hematologic cancers in individuals infected by HIV.
Blood. 2022 Feb 17;139(7):995-1012. doi: 10.1182/blood.2020005469.
10
HIV co-receptor-tropism: cellular and molecular events behind the enigmatic co-receptor switching.
Crit Rev Microbiol. 2021 Aug;47(4):499-516. doi: 10.1080/1040841X.2021.1902941. Epub 2021 Apr 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验